$94.44
2.662.9%
Last update: Oct 29, 5:03 PM
Edwards Lifesciences Corp
EWNYSE
Edwards Lifesciences (EW) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Edwards Lifesciences (EW) last issued guidance on July 23, 2026 for Q3 2026. The company guided earnings per share in the range of $0.71 - $0.77, compared to a consensus EPS estimate of $0.74. Edwards Lifesciences also guided revenue in the range of $1.63B - $1.71B for the period.
Compared to prior guidance, Edwards Lifesciences lowered its revenue forecast from a prior range of $6.6B - $6.9B.
Edwards Lifesciences has issued 39 guidance updates between December 8, 2022 and July 23, 2026. During this period, the company raised its outlook 5 times and lowered it 17 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.74 | $0.73 | $0.62 | $0.59 |
| Actual | $0.78 | $0.78 | $0.58 | $0.67 |
| Surprise | +5.41% | +6.85% | -6.45% | +13.6% |
| Revenue | ||||
| Estimate | $1.70B | $1.59B | $1.54B | $1.50B |
| Actual | $1.74B | $1.65B | $1.57B | $1.55B |
| Surprise | +2.42% | +3.41% | +1.81% | +3.66% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.74 | $0.71 | $0.84 | $0.86 |
| Revenue | ||||
| Consensus | $1.68B | $1.70B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $0.78 | $0.74 | 5.41 % |
| Q1 | Apr 23, 2026 | $0.78 | $0.73 | 6.85 % |
| Q4 | Feb 10, 2026 | $0.58 | $0.62 | -6.45 % |
| Q3 | Oct 30, 2025 | $0.67 | $0.59 | 13.6 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $1.74B | $1.70B | 2.42 % |
| Q1 | Apr 23, 2026 | $1.65B | $1.59B | 3.41 % |
| Q4 | Feb 10, 2026 | $1.57B | $1.54B | 1.81 % |
| Q3 | Oct 30, 2025 | $1.55B | $1.50B | 3.66 % |
